Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Background Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment. Method Outpatients diagnosed with DSM-IV major depressive disorder (male or female, aged 18 to 81 years) who had completed 8 weeks of randomized double-blind treatment with escitalopram, citalopram, or placebo entered an 8-week flexible-dose, open-label phase in which all patients received escitalopram (10-20 mg/day). This study was initiated November 3, 1999, and completed April 5, 2001. Patients who met responder criteria (score of or = 22 or discontinuation due to an insufficient therapeutic response) from the start of the double-blind treatment phase. Results A total of 502 patients received open-label escitalopram treatment and had at least 1 MADRS assessment. A total of 274 evaluable subjects entered the double-blind treatment phase; 93 received placebo and 181 received escitalopram. Time to depression relapse was significantly longer (p =.013) and the cumulative rate of relapse was significantly lower in patients who received escitalopram (26% escitalopram vs. 40% placebo; hazard ratio = 0.56; p =.01). Escitalopram-treated subjects had significantly lower depression ratings than those of placebo-treated patients. Escitalopram continuation treatment was safe and well tolerated. Discontinuation rates due to adverse events we…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The original DBRPCTs reported that although vilazodone did not differ from placebo in terms of relapse rate at the study-endpoint [23], escitalopram and bupropion were superior to placebo [43, 55].”
From Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis (2023) · cites this paper as [43]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
(1996) · Cited by 6,884
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
Burke, W. J., Gergel, I., & Bose, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0410 · Cited by 350
Self-citationContinuation drug therapy for major depressive episodes: how long should it be maintained?
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.1.18 · Cited by 295
Keller, M. B., & Boland, R. J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00110-3 · Cited by 281
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Cited by
Traumatic stress: effects on the brain
Bremner, J. D. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.4/jbremner · Cited by 738
Maintenance Treatment of Major Depression in Old Age
Reynolds, C. F., Dew, M. A., Pollock, B. G., Mulsant, B. H., Frank, E., Miller, M. D., Houck, P. R., Mazumdar, S., Butters, M. A., Stack, J. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052619 · Cited by 476
Morphine use after combat injury in Iraq and post-traumatic stress disorder
Holbrook, T. L., Galarneau, M. R., Dye, J. L., Quinn, K., & Dougherty, A. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903326 · Cited by 429
Posttraumatic Stress Disorder: Etiology, Epidemiology, and Treatment Outcome
Keane, T. M., Marshall, A. D., & Taft, C. T. (2006) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095305 · Cited by 366
The Clinical Pharmacokinetics of Escitalopram
Rao, N. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746040-00002 · Cited by 256
Gartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 237
Escitalopram Therapy for Major Depression and Anxiety Disorders
Baldwin, D. S., Reines, E. H., Guiton, C., & Weiller, E. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k089 · Cited by 228
Kennedy, S. H., Andersen, H. F., & Lam, R. W. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0615 · Cited by 216
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
Association between trauma exposure and delusional experiences in a large community-based sample
Scott, J., Chant, D., Andrews, G., Martin, G., & McGrath, J. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.026708 · Cited by 181
Brunoni, A. R., Lopes, M., Kaptchuk, T. J., & Fregni, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004824 · Cited by 173
“We also received data from Forest Labs of two posters [15,16] and for an unpublished trial mentioned in another study [13].”
MethodHansen, R., Gaynes, B., Thieda, P., Gartlehner, G., Deveaugh-Geiss, A., Krebs, E., & Lohr, K. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.10.1121 · Cited by 172
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152
Rapaport, M. H., Gharabawi, G. M., Canuso, C. M., Mahmoud, R. A., Keller, M. B., Bossie, C. A., Turkoz, I., Lasser, R. A., Loescher, A., Bouhours, P., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301113 · Cited by 168
Self-citationBreast-feeding Increases Sleep Duration of New Parents
Doan, T., Gardiner, A., Gay, C. L., & Lee, K. A. (2007) · Journal of Perinatal & Neonatal Nursing · doi:10.1097/01.jpn.0000285809.36398.1b · Cited by 141
Escitalopram in the treatment of major depressive disorder: A meta-analysis
Kennedy, S. H., Andersen, H. F., & Thase, M. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802622726 · Cited by 140
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136
“The original DBRPCTs reported that although vilazodone did not differ from placebo in terms of relapse rate at the study-endpoint [23], escitalopram and bupropion were superior to placebo [43, 55].”
BackgroundPrevention of relapse in generalized anxiety disorder by escitalopram treatment
Allgulander, C., Florea, I., & Huusom, A. K. T. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005973 · Cited by 132
Stein, D. J., Baldwin, D. S., Dolberg, O. T., Despiegel, N., & Bandelow, B. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1111 · Cited by 120
Murdoch, D. R., & Keam, S. J. (2005) · Drugs · doi:10.2165/00003495-200565160-00013 · Cited by 117
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115
Goethe, J. W., Woolley, S. B., Cardoni, A. A., Woznicki, B. A., & Piez, D. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815152a5 · Cited by 113
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100
Functional neuroimaging in post-traumatic stress disorder
Bremner, J. D. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.4.393 · Cited by 95
Perahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.346 · Cited by 94
Preventing Relapse and Recurrence of Depression:A Brief Review of Therapeutic Options
Thase, M. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900015212 · Cited by 93
Escitalopram Prevents Relapse in Older Patients With Major Depressive Disorder
Gorwood, P. A. P. M., Weiller, E., Lemming, O. M., & Katona, C. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000240823.94522.4c · Cited by 89
Norris, E. R., Burke, K., Correll, J. R., Zemanek, K. J., Lerman, J., Primelo, R. A., & Kaufmann, M. W. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.06.023 · Cited by 82
Thase, M. E., Larsen, K. G., & Kennedy, S. H. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.093336 · Cited by 71
Amsterdam, J. D., & Bodkin, J. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239794.37073.70 · Cited by 72
Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure
Jin, Y., Pollock, B. G., Frank, E., Cassano, G. B., Rucci, P., Müller, D. J., Kennedy, J. L., Forgione, R. N., Kirshner, M. A., Kepple, G., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337946 · Cited by 80
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Allen, N. B., Hetrick, S. E., Simmons, J. G., & Hickie, I. B. (2007) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01329.x · Cited by 61
Kornstein, S. G., Bose, A., Li, D., Saikali, K. G., & Gandhi, C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1115 · Cited by 60
Self-citationThe cardiovascular safety profile of escitalopram
Thase, M. E., Larsen, K. G., Reines, E. H., & Kennedy, S. H. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.011 · Cited by 59
Depression in adults: drug and physical treatments.
Barbui, C., Butler, R., Cipriani, A., Geddes, J. R., & Hatcher, S. (2007) · Europe PMC (PubMed Central) · Cited by 56
Escitalopram for the treatment of major depression and anxiety disorders
Höschl, C., & Švestka, J. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.4.537 · Cited by 50
Cox, G. R., Fisher, C. A., De Silva, S., Phelan, M., Akinwale, O. P., Simmons, M. B., & Hetrick, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007504.pub2 · Cited by 48
The onset of effect for escitalopram and its relevance for the clinical management of depression
Wade, A., & Friis Andersen, H. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148319 · Cited by 46
Traitement des épisodes dépressifs sévères : escitalopram est plus efficace que citalopram
Azorin, J., Llorca, P., Despiégel, N., & Verpillat, P. (2004) · L Encéphale · doi:10.1016/s0013-7006(04)95427-9 · Cited by 46
Evidence based review of escitalopram in treating major depressive disorder in primary care
Einarson, T. R. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000139342.22133.77 · Cited by 45
Escitalopram and suicidality in adult depression and anxiety
Pedersen, A. G. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00003 · Cited by 44
Papakostas, G. I., & Larsen, K. G. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0149-3 · Cited by 45
Papakostas, G. I., Fan, H., & Tedeschini, E. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.009 · Cited by 46
Escitalopram in the treatment of anxiety symptoms associated with depression
Bandelow, B., Andersen, H. F., & Dolberg, O. T. (2007) · Depression and Anxiety · doi:10.1002/da.20141 · Cited by 39
Limitations of contemporary antidepressants: tolerability.
Papakostas, G. I. (2007) · PubMed · Cited by 44
Managing depressive and anxiety disorders with escitalopram
Thase, M. E. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.4.429 · Cited by 37
Effects of antidepressants on QT interval in people with mental disorders
Aronow, W. S., & Shamliyan, T. (2020) · Archives of Medical Science · doi:10.5114/aoms.2019.86928 · Cited by 39
Management of depression relapse: Re-initiation of duloxetine treatment or dose increase
Fava, M., Detke, M. J., Balestrieri, M., WANG, F., Raskin, J., & David, P. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.06.005 · Cited by 39
Escitalopram in clinical practice: Results of an open-label trial in a naturalistic setting
Rush, A. J., & Bose, A. (2005) · Depression and Anxiety · doi:10.1002/da.20051 · Cited by 34
Self-citationWade, A. G., Toumi, I., & Hemels, M. E. H. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x41462 · Cited by 38
The effect of escitalopram on sleep problems in depressed patients
Lader, M., Andersen, H. F., & Bækdal, T. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.694 · Cited by 34
Rucci, P., Frank, E., Calugi, S., Miniati, M., Benvenuti, A., Wallace, M., Fagiolini, A., Maggi, L., Kupfer, D. J., & Cassano, G. B. (2011) · Depression and Anxiety · doi:10.1002/da.20894 · Cited by 33
New Possibilities of Treatment for Panic Attacks in Elderly Patients: Escitalopram Versus Citalopram
Rampello, L., Alvano, A., Raffaele, R., Malaguarnera, M., & Vecchio, I. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000195383.96383.25 · Cited by 32
Stein, D. J., & Lopez, A. G. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0071-8 · Cited by 35
Kamijima, K., Burt, T., Cohen, G., Arano, I., & Hamasaki, T. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182118.57510.d1 · Cited by 31
Boland, E. M., Vittengl, J. R., Clark, L. A., Thase, M. E., & Jarrett, R. B. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.10.033 · Cited by 29
Gili, M., Vicens, C., Roca, M., Andersen, P., & McMillan, D. (2014) · Preventive Medicine · doi:10.1016/j.ypmed.2014.07.035 · Cited by 34
Ou, J., Xun, G., Wu, R., Li, L., Fang, M., Zhang, H., Xie, S., Shi, J., Du, B., Yuan, X.-Q., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1822-y · Cited by 30
Baclofen Add-on to Citalopram in Treatment of Posttraumatic Stress Disorder
Manteghi, A. A., Hebrani, P., Morteza-Nia, M., Haghighi, M. B., & Javanbakht, A. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000089 · Cited by 27
Escitalopram in the Long-Term Treatment of Major Depressive Disorder in Elderly Patients
Kasper, S. F., Lemming, O. M., & de Swart, H. (2006) · Neuropsychobiology · doi:10.1159/000098650 · Cited by 25
Wu, E. Q., Greenberg, P. E., Yang, E., Yu, A., & Erder, M. H. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802303525 · Cited by 23
Leonard, B. E., & Taylor, D. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109349835 · Cited by 27
Desvenlafaxine for the treatment of major depressive disorder
Kornstein, S. G., McIntyre, R. S., Thase, M. E., & Boucher, M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.923403 · Cited by 23
Why do some promising brain-stimulation devices fail the next steps of clinical development?
Edelmuth, R., Nitsche, M. A., Battistella, L. R., & Fregni, F. (2009) · Expert Review of Medical Devices · doi:10.1586/erd.09.64 · Cited by 21
Impact of Study Design on the Results of Continuation Studies of Antidepressants
Zimmerman, M., Posternak, M. A., & Ruggero, C. J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31803308e1 · Cited by 20
Jin, Y., Pollock, B. G., Frank, E., Florian, J., Kirshner, M. A., Fagiolini, A. M., Kupfer, D. J., Gastonguay, M. R., Kepple, G., Feng, Y., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008327538 · Cited by 21
Tachyphylaxis/ tolerance to antidepressive medications: a review.
Katz, G. (2011) · PubMed · Cited by 23
Mallinckrodt, C., Chuang‐Stein, C., McSorley, P., Schwartz, J., Archibald, D. G., Perahia, D. G., Detke, M. J., & Alphs, L. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.234 · Cited by 18
Allen, N. B., Hetrick, S. E., Yap, M. B. H., & Simmons, J. G. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007504 · Cited by 15
Zhou, D., Lv, Z., Shi, L., Zhou, X., Lin, Q., Chen, X., Wan, L.-Y., Li, Y., Ran, L., Huang, Y., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720001610 · Cited by 14
Arano, I., Sugimoto, T., Hamasaki, T., & Ohno, Y. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-33 · Cited by 13
Zaccoletti, D., Mosconi, C., Gastaldon, C., Benedetti, L., Gottardi, C., Papola, D., Ponzi, O., Purgato, M., Naudet, F., Cristea, I. A., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00330-x · Cited by 13
Nordstrom, G., Danchenko, N., Despiégel, N., & Marteau, F. (2012) · Value in Health · doi:10.1016/j.jval.2011.09.011 · Cited by 11
Umucu, E., Rumrill, P. D., Chiu, C., & Ghosh, A. (2022) · Rehabilitation Research Policy and Education · doi:10.1891/re-21-04 · Cited by 11
Citalopram and suicidality in adult major depression and anxiety disorders
Pedersen, A. G. (2006) · Nordic Journal of Psychiatry · doi:10.1080/08039480600937561 · Cited by 12
Tandon, V., Gupta, B., Zargar, S., & Arora, M. (2016) · Perspectives in Clinical Research · doi:10.4103/2229-3485.173771 · Cited by 11
Lam, R. W. M., & Annemans, L. (2007) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.7.6.559 · Cited by 10
Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
Shao, S., Sun, B., & Sun, H. (2022) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.38.5.5230 · Cited by 10
Oakes, T. M. M., Dellva, M. A., Waterman, K., Greenbaum, M., Poppe, C. J., Goldberger, C., AHL, J. S. B., & David, P. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1037732 · Cited by 11
Winkler, D., Pjrek, E., Moser, U., & Kasper, S. F. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.839 · Cited by 11
Lançon, C., Verpillat, P., Annemans, L., Despiégel, N., & François, C. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600874527 · Cited by 9
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8
Boyer, P., Vialet, C., Hwang, E., & Tourian, K. A. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01711 · Cited by 9
Sado, M., Wada, M., Ninomiya, A., Nohara, H., Kosugi, T., Arai, M., Endo, R., & Mimura, M. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12851 · Cited by 9
Lecrubier, Y., Dolberg, O. T., Andersen, H. F., & Weiller, E. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0771-x · Cited by 9
Wu, E., Ben-Hamadi, R., Yu, A., Tang, J., Erder, M., & Bose, A. (2010) · Journal of Medical Economics · doi:10.3111/13696998.2010.488985 · Cited by 8
Self-citationSpotlight on Escitalopram in the Management of Major Depressive Disorder1
Murdoch, D., & Keam, S. J. (2006) · CNS Drugs · doi:10.2165/00023210-200620020-00007 · Cited by 8
The importance of long-term tolerability in achieving recovery
Baldwin, D. S. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600552552 · Cited by 8
Liu, S., Xiao, T., Huang, S., Li, X., Kong, W., Yang, Y., Zhang, Z. M., Ni, X., Lu, H., Zhang, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964758 · Cited by 9
A Behavior Analytic Perspective on Treatment of Problem Gaming and Problem Social Media Use
Hassan, M., & Kyonka, E. G. E. (2021) · The Psychological Record · doi:10.1007/s40732-021-00465-y · Cited by 8
Arıkan, M. K., İlhan, R., Pogarell, O. M., & Metin, B. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.024 · Cited by 6
Schmitt, L., Tonnoir, B., & Arbus, C. (2006) · Neuropsychobiology · doi:10.1159/000100368 · Cited by 6
Guidelines in major depressive disorder, and their limitations
Montgomery, S. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600940492 · Cited by 6
Xie, F., Despiégel, N., Danchenko, N., & Hansen, K. (2008) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500802450506 · Cited by 5
Diagnosis and Treatment of Major Depression 2007
Patricia, D., & Price, D. W. (2007) · The Permanente Journal · doi:10.7812/tpp/07-038 · Cited by 6
Kongsakon, R., & Bunchapattanasakda, C. (2008) · PubMed · Cited by 4
Nakagome, K., Yokoi, Y., Nakagawa, A., Tani, M., Nishioka, G., Yoshimura, N., Furukawa, T. A., Watanabe, K., Mimura, M., Iwanami, A., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.148 · Cited by 5
Psychopharmakotherapie – Klinisch-empirische Grundlagen
Kasper, S., & Möller, H.-J. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_28 · Cited by 3
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_31 · Cited by 3
Metadata
- Authors
- Rapaport, M. H., Bose, A., & Zheng, H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-01-15
- Volume
- 65
- Issue
- 1
- Pages
- 44-49
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2077027462
- Cited by
- 121
- References
- 24
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 6 · 2014: 5 · 2013: 1 · 2012: 3
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- escitalopram, continuation treatment, relapse prevention, major depressive disorder, antidepressant efficacy, citalopram, open-label extension, adverse events, treatment safety
- MeSH terms
- Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Placebos, Prognosis, Psychiatric Status Rating Scales, Recurrence, Citalopram, Treatment Outcome, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.